Resources from the same session
Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
Presenter: Corey Langer
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
Presenter: Fabrice Barlesi
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator’s choice (IC): CheckMate 141
Presenter: Kevin Harrington
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Presenter: Martin Reck
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
Invited discussant LBA46_PR and LBA8_PR
Presenter: Jean-Charles Soria
Session: Presidential Symposium 2
Resources:
Presentation
Invited discussant LBA4_PR
Presenter: Anthony Tak Cheung Chan
Session: Presidential Symposium 2
Resources:
Presentation
CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Presenter: Mark Socinski
Session: Presidential Symposium 2
Resources:
Abstract
Presentation